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Abstract
Background: Oxidative stress play a main role in the initiation and progression of the OA disease and leads to the
degeneration of mitochondria. To prevent this, the chondrocytes possess a well-coordinated enzymatic antioxidant
system. Besides, the mitochondrial DNA (mtDNA) haplogroups are associated with the OA disease. Thus, the main
goal of this work is to assess the incidence of the mtDNA haplogroups on serum levels of two of the main
antioxidant enzymes, Manganese Superoxide Dismutase (Mn-SOD or SOD2) and catalase, and to test the suitability
of these two proteins for potential OA-related biomarkers.
Methods: We analyzed the serum levels of SOD2 and catalase in 73 OA patients and 77 healthy controls carrying
the haplogroups J, U and H, by ELISA assay. Knee and hip radiographs were classified according to Kellgren and
Lawrence (K/L) scoring from Grade 0 to Grade IV. Appropriate statistical analyses were performed to test the effects
of clinical variables, including gender, body mass index (BMI), age, smoking status, diagnosis, haplogroups and
radiologic K/L grade on serum levels of these enzymes.
Results: Serum levels of SOD2 appeared statistically increased in OA patients when compared with healthy
controls (p < 0.001). Even in those OA patients with higher OA severity (K/L grade IV), the serum levels of this
antioxidant enzyme appeared more significantly increased than in OA patients with lower K/L grade (p < 0.001).
The mtDNA haplogroups showed an influence on serum levels of catalase (p = 0.054), being carriers of the mtDNA
haplogroup J those who showed higher serum levels than non-J carriers (p = 0.057).
Conclusions: The increased levels of SOD2 in OA patients indicate an increased oxidative stress OA-related,
therefore this antioxidant enzyme could be a suitable candidate biomarker for diagnosis of OA. Mitochondrial
haplogroups significantly correlates with serum levels of catalase
Background
Osteoarthritis (OA), the most common joint disease and
cause of musculoskeletal disability in elderly people, is
characterized by late-onset degeneration of articular car-
tilage, leading to joint destruction and severe impair-
ment of mobility [1]. It is also the main cause of work
incapacity and one of the most common reasons for vis-
iting primary physicians. The metabolic and structural
changes that take place in the articular cartilage,
including the oxidative stress, are thought to play a
main role in the initiation and progression of this
disease.
Actually, OA-related molecular biomarkers are being
developed with the aim of detecting the progression of
OA with more reliability and sensitivity, preferably early
in the disease process [2,3]. Because of their greater sen-
sitivity compared with radiographs, several molecular
markers for bone, cartilage and synovial have been
described as useful for the early identification of OA
and of patients at high risk for progression, for monitor-
ing disease progression, and for assessing therapeutic
response [3-6]. In this sense, our group has recently
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drial DNA (mtDNA) haplogroups, which we suggest can
be useful as complementary factors when the classical
OA-related molecular biomarkers are analyzed.
The mtDNA haplogroups have been associated not
only with several multifactorial diseases [7-9] and ageing
[10,11], but also with a lower prevalence and severity of
knee and hip OA [12,13]. Besides, they modulate the
serum levels of some collagen type-II molecular biomar-
kers [14] as well as some proteolytic enzymes, such as
metalloproteinases [15]. The proposed mechanism relies
on the different metabolic characteristics of these hap-
logroups, reflected by the performance of the mitochon-
drial oxidative phosphorylation system (OXPHOS) of
each haplogroup [7,16]. The OXPHOS system is a mito-
chondrial metabolic pathwayt h a tu s e se n e r g yr e l e a s e d
by the oxidation of nutrients to produce adenosine tri-
phosphate (ATP) as electrons are transferred from elec-
tron donors to electron acceptors, such as oxygen, in
redox reactions. These redox reactions, carried out by a
series of protein complexes within mitochondria, release
energy which is used to form ATP.
The different metabolic characteristics make hap-
logroup J carriers to show not only lower serum levels
of catabolic OA-related biomarkers when compared
with those carriers of the haplogroup H [14] but also
lower oxygen consumption and lower oxidative damage
[17].
As mentioned above, elevated levels of oxidative stress
occur in OA and aged cartilage [18]. Although reactive
oxygen species (ROS) are involved in the control of var-
ious aspects of biological processes in chondrocytes as
intracellular second messenger molecules [19], elevated
production of ROS leads to i) telomere instability and
downregulation of chondrocyte function [20], ii)
increased inflammatory response [21], iii) cartilage
degradation, by cleaving collagen and aggrecan and acti-
vating matrix metalloproteinases (MMPs) [22], and iv)
cell death [23]. Oxidative stress also results in the
degeneration of mitochondria, the main source of ROS,
leading to a leakage of oxidative chain and significant
damage to the mitochondrial genome and reduced
mtDNA capacity for repair [24].
To prevent an accumulation of ROS-mediated
damage, chondrocytes possess a well-coordinated enzy-
matic antioxidant system formed principally by superox-
ide dismutases (SODs), catalase and glutathione
peroxidase (GPX). SOD2 and SOD3 has been shown to
be downregulated in OA cartilage [25-27]; and catalase
activity was shown to be increased in OA patients com-
pared with healthy controls [28].
In summary, taking into account the incidence of the
oxidative stress in the OA process, as well as the inci-
dence of the mtDNA haplogroups in both the
performance of the OXPHOS system and in the OA dis-
ease, even on serum levels of classical OA-related mole-
cular biomarkers and proteolytic enzymes, the aim of
this work is to perform a retrospective study to evaluate
the effects of the mtDNA haplogroups on serum levels
of SOD2 and catalase, as well as to test the suitability of
these two proteins for potential OA-related biomarkers.
The study population is a previously described cohort of
OA patients and healthy controls from the north of
Spain, consisted in 73 OA subjects and 77 healthy con-
trols carrying the mtDNA haplogroups J, U or H [14].
Methods
Subjects
The population analyzed in this study has been
described previously [14]. A total of 73 unrelated
patients diagnosed with knee or hip OA (25 carrying
haplogroup J, 25 carrying haplogroup U and 23 carrying
haplogroup H) were included in the present study.
Patients meeting the inclusion criteria for this study
included individuals of both sexes (52 females; 21
males), older than 41-years-old (mean age: 67.74 ± 8.96
years-old; range: 51-95), and diagnosed with OA follow-
ing the American College of Rheumatology (ACR) cri-
teria [29]. Knee and hip radiographs from 148 subjects
were classified according to Kellgren and Lawrence (K/
L) scoring from Grade 0 to Grade IV [30]. Only those
joints of OA patients diagnosed with OA were examined
for presence of radiographic OA. Of the 77 subjects who
met the inclusion criteria for normal subjects, 25 carried
haplogroup J, 25 haplogroup U and 27 haplogroup H.
These control subjects included 39 females and 38
males older than 41-years-old (mean age: 66.01 ± 11.88
years-old; range: 42-94), who did not meet the ACR cri-
teria for knee or hip OA. In all cases, informed consent
and the agreement of the ethical committee from Gali-
cian Health Administration were obtained.
mtDNA haplogroups genotyping
The samples obtained for the study were haplogroup-
t y p e du s i n gap r e v i o u s l yd e s c r i b e da s s a y[ 1 2 ] .B r i e f l y ,a
multiplex PCR for the amplification of 6 mtDNA frag-
ments that contain 6 informative mtDNA single nucleo-
tide polymorphisms (SNPs) was performed, followed by a
single base extension assay (SBE) prior purification of the
amplified PCR products. Finally, the fragments were run
in an automatic DNA sequencer (ABI 3130XL) to assign
the mtDNA haplogroups based on the combination of the
informative mtDNA SNPs. For this study, only subjects
carrying mtDNA haplogroups J, H or U were included.
Molecular biomarkers
Fasting blood samples were collected from each subject
in plain tubes containing separation gel. These were
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Page 2 of 7allowed to stand for 20 minutes, then centrifuged for 10
minutes at 800 g. The serum was then divided into ali-
quots and stored at -80°C pending assay.
For this study, the serum levels of two antioxidant
enzymes were measured: SOD2 and catalase. They were
measured in our facilities using enzyme-linked immuno-
sorbent assays (ELISAs) according to the manufacturer’s
recommendations. Serum SOD2 levels were measured
using a kit from ABfrontier (Republic of Korea) and cat-
alase was measured using a Camel catalase ELISA kit
from Cusabio Biotech (Wuhan, China).
Determination of the serum levels of these enzymes
was performed by simultaneously assaying OA patients
and healthy controls, regardless of the mtDNA
haplogroup.
Statistical analysis
Statistical analyses were performed using SPSS software,
release 17 (Chicago, USA). In univariate analysis, a non-
parametric study was performed utilizing the Mann-
Whitney U-test to compare serum molecular marker
concentrations between OA patients and healthy con-
trols. The Kruskal-Wallis test was used to compare
molecular marker concentrations among the three hap-
logroups (J, U and H) regardless of the diagnosis. To
look for possible correlations among the two enzymes
analyzed, a correlation analysis using Spearmans Rho
was used. In all cases, the Bonferroni correction for
multiple comparisons was applied. Thus, p-values were
obtained after multiplying the number of outcomes
tested by the number of haplogroups (k = 2 × 3).
Following these preliminary analyses, an analysis of
covariance (ANCOVA) was used to evaluate the effects
on enzyme serum levels (dependent variable) of each of
the haplogroups as well as diagnosis, adjusting for the
confounder effects of gender, body mass index (BMI),
smoking status and age. When a significant effect was
found either in haplogroups or in diagnosis, the conser-
vative Bonferroni post hoc multiple comparisons test
was performed to compare group means. If the interac-
tion between diagnosis and haplogroup was statistically
significant main effects should not be interpreted, so
differences among the 2 × 3 = 6 possible combinations
of diagnosis (OA and healthy control) and haplogroups
( H ,Ja n dU )w e r ea n a l y z e db yu s i n gt h es a m eB o n f e r -
roni post hoc multiple comparisons test. Before the
multivariate analysis, a distribution analysis using the
Kolmogorov-Smirnov test showed that the both SOD2
and catalase were not normally distributed; therefore,
their concentrations were square and log transformed
respectively to obtain a normal distribution. Model diag-
nostic statistics were also analysed using residual plots.
The influence of radiographic grade to the serum
levels of the molecular markers was tested using the
non-parametric Jonckheere-Terpstra test for ordered
groups. For this approach we obtained the radiographic
grade of 148 subjects out of the 150 that are part of the
study. Using K/L scores, subjects were divided into
three radiographic groups: group A included 77 healthy
controls (K/L grade 0 and grade I), group B consisted of
47 OA patients with K/L grades II and III, and group C
included 24 OA patients with K/L grade IV.
Results
Non-parametric analysis of serum levels of the molecular
markers
We first compared the serum levels of the enzymes
assayed between OA patients and healthy controls. The
r e s u l t ss h o w e dt h a tl e v e l so fS O D 2w e r es i g n i f i c a n t l y
increased in OA patients (p < 0.001) (Table 1). Serum
levels of catalase showed a non significant trend toward
increased values in OA patients, compared to healthy
controls (Table 1).
Interestingly, the haplogroups have a significant influ-
ence on serum levels of catalase regardless of diagnosis,
so that carriers of haplogroup J showed higher levels of
catalase (p = 0.054). Regarding to SOD2, the results did
not reach the statistical significance, but a trend toward
decreased serum levels in carriers of haplogroup H com-
pared with non-H carriers was detected (Table 2).
When we compared the three groups based on the K/
L score, only SOD2 showed a significant trend towards
proportionally higher serum levels in both groups B (K/
L grade II and III) and C (K/L grade IV) than in group
Table 1 Serum levels of molecular markers in healthy controls and osteoarthritis (OA) patients
Healthy controls
(n = 77)
OA (n = 73)
Markers Mean (SD) Median Mean (SD) Median p*
SOD2
(ng/mL)
20.83 (30.81) 13.50 36.38 (11.16) 36.41 < 0.001**
Catalase
(ng/mL)
14.50 (27.68) 5.03 21.88 (40.94) 8.00 0.189
(*) Mann-Whitney non-parametric U-test
(**) indicates statistical significance alter Bonferroni correction (p ≤ 0.05)
SD = Standard deviation
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significant correlations among the serum levels of these
two enzymes were detected.
Multiple regression analysis
We then performed a multiple regression analysis to
assess the effects of the mtDNA haplogroups and clinical
variables including gender, age, BMI, smoking status and
diagnosis on the serum levels of the enzymes analyzed.
The results obtained for SOD2 showed that serum
levels of this antioxidant enzyme were significantly
increased in OA patients compared to healthy controls
(p < 0.001). On the contrary, no significant influence of
the mtDNA haplogroups neither significant interactions
between mtDNA haplogroups and diagnosis were
detected (Table 4).
The results of the multiple regression analysis for cat-
alase showed that serum levels were slightly modulated
by the mtDNA haplogroup J, bordering on the statistical
significance, so that carriers of this haplogroup have
higher levels than non carriers (p = 0.057) (Table 4).
On the contrary, carriers of the mtDNA haplogroup U
showed a non-significant trend towards lower levels of
catalase than non-U carriers (p = 0.075) (Table 4).
However, as described for SOD2, no significant
interactions between mtDNA haplogroups and diagnosis
were found.
Discussion
In this study we analyzed whether some biomarkers
related to the oxidative stress are modulated by the
mtDNA haplogroups in the context of the OA disease.
The choice of the mtDNA haplogroups J and U was due
to their role in the prevalence and severity of knee and
hip OA [12,13]; the mtDNA haplogroup H was also
selected because is the most frequent mtDNA hap-
logroup in European populations [31].
Both SOD2 and catalase are two of the main members
of the well-coordinated enzymatic antioxidant system in
chondrocytes since ROS are, besides matrix metallopro-
teinases, the main biochemical factors of cartilage degra-
dation [32]. Briefly, SOD2 catalyses the dismutation of
superoxide anion (O2
-)t oo x y g e n( O 2)a n dh y d r o g e n
peroxide (H2O2), and this H2O2 in turn is eliminated by
catalase, the most efficient enzyme for the degradation
of H2O2, or by glutathione peroxidase. An imbalance in
this coordinated system will lead to the increased oxida-
tive stress that takes place in the OA disease.
mtDNA haplogroups have been described to be
involved in the development of the OA disease [12,13],
Table 2 Serum levels of molecular markers in the mitochondrial DNA (mtDNA) haplogroups H, U and J
Haplogroup H (n = 50) Haplogroup U (n = 50) Haplogroup J (n = 50)
Markers Mean (SD) Median Mean (SD) Median Mean (SD) Median p*
SOD2 (ng/mL) 23.27 (13.92) 24.88 31.34 (34.52) 26.29 30.70 (19.60) 30.68 0.149
Catalase (ng/mL) 21.20 (37.49) 5.22 8.37 (11.34) 4.37 25.14 (45.42) 8.57 0.054**
(*) Kruskal-Wallis non-parametric test
(**) indicates statistical significance alter Bonferroni correction (p ≤ 0.05)
SD = Standard deviation
Table 3 Demographics of the study population and serum levels of enzyme markers grouped by radiological severity
(Kellgren/Lawrence Score) and distribution of the haplogroups H, U and J in the 3 radiographic groups
Healthy controls (n = 77) OA patients (n = 73)
Mean age (range) 66.01 years-old (42-94) 67.74 years-old (51-95)
Females/Males 39 females/38 males 52 females/21 males
Haplogroups Group A (n = 77)
K/L grade 0 and I
Group B (n = 47)
K/L grade II and III
Group C (n = 24)
K/L grade IV
Haplogroup H, n(%) 25 (32.5) 18 (38.3) 7 (29.2)
Haplogroup U, n(%) 25 (32.5) 12 (25.5) 13 (54.2)
Haplogroup J, n(%) 27 (35) 17 (36.2) 4 (16.7)
Markers Mean (SD) Median Mean (SD) Median Mean (SD) Median J-T p*
SOD2 (ng/mL) 20.83 (30.81) 13.50 35.75 (10.44) 35.02 38.10 (12.74) 39.23 7.796 < 0.001**
Catalase (ng/mL) 14.50 (27.68) 5.03 22.82 (42.49) 8.56 20.58 (38.87) 8.00 1.227 0.220
Group A: K/L grade 0 and I; Group B: K/L grade II and III; Group C: K/L grade IV
(*) Jonckheere-Terstra (J-T) non-parametric test
J-T = established J-T statistic
(**) indicates statistical significance after Bonferroni correction (p ≤ 0.05)
SD = Standard deviation
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sical collagen type-II molecular biomarkers [14] and
proteolytic enzymes [15], probably due to their different
OXHPOS performance [7,16] and the differences in the
oxidative damage and oxygen consumption among them
[17]. These particular characteristics make that some of
these haplogroups show a lower ROS production and
apoptosis [33,34], hence their involvement on serum
levels of certain antioxidant proteins is a matter of
relevance.
The results obtained in this work showed that SOD2
was significantly increased in OA patients, even those
OA patients with higher radiographic grade showed the
highest values too; meanwhile catalase showed a trend
toward higher levels in the OA group, but did not reach
the statistical significance. The results obtained also
showed a influence of the mtDNA haplogroups on
serum levels of catalase, so that those carriers of the
mtDNA haplogroup J showed higher levels of catalase
than non-J carriers regardless of diagnosis.
D e s p i t es o m ea u t h o r ss h o w e dad o w n r e g u l a t i o no f
SOD2 in OA cartilage [27,35], the increased serum
levels of this enzyme in OA patients showed in this
work reflect an increased oxidative stress OA-related, as
described by other authors [36]; besides, the deleterious
effects of increased SOD2 have been supported in var-
ious studies [37]. However, serum levels of catalase were
non-significantly increased in OA patients, notwith-
standing the fact that catalase has greater stability than
SOD2 [28,32]; on the contrary, catalase was increased in
carriers of haplogroup J, showing a different pattern
than for SOD2.
Despite the influence of the haplogorup J on serum
levels of catalase, the potential role of the mtDNA hap-
logroups on serum levels of these two antioxidant
enzymes seems slight, contrarily to the observed in both
collagen type II biomarkers and proteolytic enzymes
[14,15]. Hence, a future approach will be to analyze the
serum levels of these two antioxidant enzymes in a pro-
spective larger cohort of samples to ascertain their
increased serum levels in OA patients and therefore to
validate their suitability as candidate OA biomarkers,
and even their modulation by the mtDNA haplogroups.
Attending to the “BIPED” (Burden of disease, Investi-
gative, Prognostic, Efficacy of intervention and Diagnos-
tic) biomarker classification [38], SOD2 could be
considered as a diagnostic marker pending validation,
and also a burden of disease marker since, as shown in
this study, its serum levels are significantly different
attending to the K/L score. Regarding to the mtDNA
haplogroups, they could be considered as investigative
markers because, although their combination with some
of the OA-related biomarkers seems to influence their
behaviour, to increase information and replicate the
findings to allow inclusion into one of the existing cate-
gories is still necessary. Otherwise, because we did not
find significant differences in serum levels of catalase
between OA patients and healthy controls, we consider
this potential biomarker as another investigative one.
Biochemical markers of cartilage degradation have
received much attention in comparison with others;
overall, uCTX-II and sCOMP had the best performance
of all currently biochemical markers, they were investi-
gated most frequently and broadly, and scored in the
higher ranges of scores form most “BIPED” categories;
however, none of the current biochemical markers is
sufficiently discriminating to aid diagnosis and/or prog-
nosis of OA, attending to a systematic review carried
out by Spil van and collaborators [39].
This study show some limitations that must be con-
sidered. This is a retrospective study in which the selec-
tion of the samples was based on the availability of
serum samples carrying the mtDNA haplogroups J, U or
H with no criterion when obtaining the serum samples;
in this sense, it must be pointed out that, for serological
analysis, the standardization of sample collection may
improve biochemical marker performance since diurnal
rhythms and influences of exercise have been described
for several biochemical markers [40,41]; besides,
repeated thawing and freezing must be avoided in order
to obtain reliable results. Otherwise, the sample size
may be small when multiple analysis are performed, and
specially if we compare with larger GWAS studies,
although this work is not. Hence, more samples must be
analyzed to replicate these findings, and therefore we
have initiated a new prospective collection of samples to
try to replicate the findings showed in this study.
Conclusions
To our knowledge, this is the first work that correlates
the serum levels of these enzymes with the mtDNA
Table 4 p values from the ANOVA table for the analysis
of covariance of serum levels of the two enzymes
analyzed
Variable SOD2 Catalase
Gender 0.422 0.536
Age 0.800 0.211
BMI 0.655 0.471
Smoking status 0.785 0.084
Diagnosis < 0.001* 0.249
Haplogroups:
Haplogroup H (vs non-H) 0.133 0.894
Haplogroup J (vs non-J) 0.580 0.057*
Haplogroup U (vs non-U) 0.354 0.075
Diagnosis X Haplogroup 0.488 0.883
(*) indicates statistical significance (p ≤ 0.05)
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mary, this work highlights the significantly increased
serum levels of SOD2, an important antioxidant enzyme,
in OA patients, demonstrating the existence of oxidative
stress. Besides, serum levels of catalase are slightly
increased in carriers of the mtDNA haplogroup J, when
compared with non-J carriers. As described for both
type II collagen biomarkers and some proteolytic
enzymes OA-related, the influence of the haplogroups
on the serum levels of catalase could arise from the dif-
ferent metabolic characteristics of these mitochondrial
variants, that make some of them showed a different
performance of the OXPHOS system [7,16]. Similarly,
since serum levels of SOD2 are significantly decreased
in healthy controls and significantly increased in OA
patients with K/L grade IV, the use of SOD2 as a candi-
date biomarker for diagnosis of OA is proposed. How-
ever, a new prospective study must be performed in
order to replicate these findings.
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